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β-blockers in septic shock: are we there yet?
COMMENTARY
Background
Septic shock is characterized by circulatory collapse and diminished tissue 
perfusion, leading to organ dysfunction in the setting of systemic infection. 
The mechanisms of septic shock are incompletely understood; moreover, 
its incidence is increasing, and its mortality remains unacceptably high. In 
addition to antimicrobial and supportive treatments, no other therapy has a 
survival benefit, despite multiple attempts at developing one.(1) With the article 
by Morelli et al.,(2) a new hope has emerged.
Septic shock and the adrenergic system
The adrenergic system plays a key role in modulating cardiovascular, immune, 
hemostatic and metabolic functions. It is upregulated in septic shock through 
the activation of different adrenoreceptors that have distinct and sometimes 
opposite effects.(3) The adrenergic system serves as an initial adaptive response to 
maintain homeostasis by elevating heart rate, stroke volume and mean arterial 
pressure, keeping the balance of inflammation and coagulation and providing 
sufficient nutrients to cells. However, over the long term, the high output of 
endogenous catecholamines causes an imbalance in this regulatory function 
and perpetuates organ dysfunction.(4) To make matters worse, there is also an 
adrenergic storm caused by the use of vasopressor therapy, which is the mainstay 
of supportive treatment for fluid-unresponsive septic shock.(1) Noradrenaline, 
adrenaline and dopamine are used for their α-adrenergic vasoconstrictor effects, 
but they also act upon β-adrenergic receptors, mainly β1.
As such, they can promote tachydysrhythmias and cardiomyopathy and 
upregulate inflammatory and coagulation pathways,(3,4) which is deleterious.
Sepsis-induced cardiomyopathy
A particular occurrence in septic shock is the development of cardiac 
dysfunction. The definition of sepsis-induced cardiomyopathy is not 
established, but it is historically characterized by reduced left ventricular 
(LV) ejection fraction, LV dilation and complete recovery in 7 to 10 days.(5) 
Right ventricular (RV) dysfunction and dilation are also observed.(6) Its cause 
is not completely understood, but inflammatory mediators and adrenergic 
hyperstimulation are important contributors to impairing myocyte signaling 
transduction and reducing cardiac contractility. Tachycardia, which is common 
in septic shock and is a known predictor of poor prognosis, promotes cardiac 
dysfunction by increasing oxygen requirements and diminishing diastolic 
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cardiac filling and coronary perfusion. An estimated 
50% of septic shock patients develop cardiomyopathy, 
as assessed by echocardiography.(5) However, considering 
that the LV ejection fraction is dependent not only on 
LV contractility but also on pre- and afterload (that are 
in turn related to the quantity of fluids and vasopressors 
imposed on each patient), cardiac dysfunction would 
likely be present in virtually all patients with septic shock 
if they were evaluated using a method less dependent on 
the degree of resuscitation. Contrary to previous beliefs, 
there is currently no clinical evidence that links LV or 
RV systolic dysfunction or dilation to prognosis in septic 
shock.(6) Nevertheless, a recent meta-analysis reported that 
diastolic dysfunction, which may be more common, is 
related to mortality.(7)
Septic shock and β-blockers
There has been a growing interest in the use of 
β-blockers in septic shock. It was hypothesized that the 
administration of β1-selective blockers could protect 
patients from the toxicity of endogenous and exogenous 
catecholamines and ameliorate cardiac function and the 
homeostasis of immunologic and coagulation processes. 
These effects have already been proven in animal models. 
However, the results for prognosis have not been 
consistent,(3) and some concerns about the danger of 
precipitously reducing cardiac output and blood pressure 
remained.
The first randomized clinical trial (RCT) conducted to 
assess the effect of β-blockade on tachycardia and other 
hemodynamic parameters in septic shock enrolled 154 
patients who remained tachycardic (heart rate (HR) > 94 
beats per minute (bpm)) and on a noradrenaline infusion 
after 24 hours of standard resuscitation. Half of them 
were randomized to receive an esmolol infusion, and all 
patients in this group achieved the target HR (80 - 94 
bpm) with no adverse effects on systemic or pulmonary 
hemodynamics. In fact, stroke volume increased, 
which suggests an optimization of cardiac efficiency 
and myocardial oxygen utilization. There was also an 
improvement in perfusion markers, such as arterial lactate 
and pH, oxygen consumption and estimated glomerular 
filtration rate. Fluid and vasopressor requirements were 
decreased, and, most importantly, there was a significantly 
lower 28-day mortality in the patients who received 
esmolol.(2)
While systemic hemodynamic parameters are 
accessible for monitoring patients with circulatory 
collapse, the cornerstone of organ dysfunction in 
septic shock is the microcirculation, which is less easily 
assessed in everyday clinical practice.(8) The same authors 
published a pilot study that added the evaluation of the 
sublingual microcirculation to a similar design. They 
noted an improvement in two parameters (blood flow and 
heterogeneity index), whereas the other two (De Baker 
score and perfused vessel density) were unchanged in the 
group receiving esmolol. While it is safe to conclude that 
β-blockade poses no danger to the microcirculation, it is 
not possible to assume that there was an improvement in 
this vascular bed.(9)
Limitations of the current randomized clinical trial
Although it is clear that there is a theoretical rationale 
for using selective β-blockers that is supported by animal 
studies, the clinical evidence is still scarce, and many 
questions remain to be answered.
The RCT by Morelli et al. showed a significant survival 
benefit (albeit no independent effect of esmolol on 
mortality was found in the multivariate analysis), but the 
trial was not designed for this purpose, and the mortality 
was extremely high in the control group.(2) This raises the 
concern that there might be a bias in patient selection, 
in which the persistence of tachycardia after 24 hours of 
resuscitation is related to worse prognosis. It is not known 
whether less severe patients would derive a similar benefit. 
Additionally, half of the patients received the inodilator 
levosimendan (that improves diastolic function), and its 
influence on outcome is unknown. The other studies that 
address the influence of β-blockers on mortality either 
show a neutral effect or are flawed in their design and 
preclude the extrapolation of the results to the general 
population.(10)
Another issue is the fact that most studies published to 
date rely on reducing tachycardia to obtain an improvement 
in cardiac function.(4) It is unknown whether the mortality 
benefit is produced by the treatment of tachycardia itself 
or by its effect on cardiac function. Because there is no 
relationship between systolic dysfunction and prognosis,(6) 
it is possible that the improvement in stroke volume is not 
solely responsible for the mortality benefits. However, it is 
reasonable to hypothesize that the reduction in heart rate 
would have beneficial effects on diastolic function, as well 
by augmenting diastolic filling time, and could potentially 
confer an improvement in prognosis.(7) Unfortunately, 
this is only speculative, as no diastolic parameters were 
assessed. Additionally, no study assessed the optimal heart 
rate in septic shock, as the targets for its reduction were 
arbitrarily set.(2,9,10)
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An additional matter to be discussed is the fact that 
sinus tachycardia is often a response to an insult, such as 
fever, anxiety, pain, anemia, hypoxemia, thyrotoxicosis, 
electrolyte and acid-base abnormalities.(11) These factors 
should be frequently monitored and thoroughly addressed 
before true deleterious tachycardia, caused solely by 
hyperadrenergic status, is treated with β-blockers. The role 
of heart rate in guiding the management of critically ill 
patients would also be lost if the use of β-blockers in septic 
shock were to become widespread. In particular, volume 
status/fluid responsiveness and autonomic nervous system 
function are important issues in intensive care patients. 
Nevertheless, static hemodynamic measurements are 
presently being replaced with dynamic ones for the 
assessment of volume status/fluid responsiveness,(12) and 
a number of methods for autonomic nervous system 
evaluation beyond those dependent on heart rate are being 
developed.(13) Nevertheless, it would be useful to have a 
clear view of how to monitor these patients.
Furthermore, only one non-randomized prospective trial 
evaluated the effect of β-blockers on microcirculation, and 
the results were not conclusive.(9) Because microcirculation 
appears to play a more important role than macrocirculation 
in sepsis,(8) it would be essential to understand the action of 
β-blockers on the microvascular bed.
Lastly, given the ubiquitous distribution of the 
adrenergic system, it cannot be excluded that β-blockers 
could also exert their influence on outcome through 
their non-cardiac anti-inflammatory and anticoagulation 
effects.
Conclusion
The potential benefits of β-blockers in septic shock 
patients are vast and include the amelioration of cardiac 
function and microcirculation, anti-inflammatory and 
anticoagulation effects, and survival benefits. However, 
although very promising, there is currently not enough 
evidence to advise the use of β-blockers in everyday 
practice, and there is an urgent need for more studies. 
Two large RCTs (ESMOSEPSIS - Esmolol Effects on 
Heart and Inflammation in Septic Shock and THANE - 
Hemodynamic Tolerance and Anti-inflammatory Effects 
of Esmolol During the Treatment of Septic Shock) are 
presently recruiting and should provide new insight into 
the effects of β-blockers on systemic hemodynamics, 
including diastolic function and microcirculation, as well 
as the immune system and mortality; hopefully, these 
RCTs will provide a better understanding of the selection 
process of the ideal patients for this therapy and how to 
monitor them.
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